Editors’ notes
This article has been reviewed according to Science X’s
editorial process
and policies.
Editors have highlighted
the following attributes while ensuring the content’s credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
by St. Jude Children’s Research Hospital
Crystal structure of PXR LBD in complex with SJPYT-310. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-48472-1
Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs. This causes a significant drop in the effectiveness of chemotherapy, antivirals and other pharmaceuticals.
Blocking the PXR activity is notoriously difficult, as many drugs that bind the protein, whether intentionally or unintentionally, activate it. Scientists at St. Jude Children’s Research Hospital have leveraged chemical and structural studies in the design of PXR inhibitors to better understand this process.
The findings, published in Nature Communications, provide new insights into the relationship between compounds that activate PXR and ones that block its activity, with implications for designing more effective therapeutics.
Removing toxic compounds from our bodies is a vital process to maintain overall health and well-being. To accomplish this, the human body has a toxin removal system. A family of proteins called cytochrome P450 plays a significant role in this process; however, these proteins do not discriminate between toxins and well-intentioned therapeutics.
Higher drug doses are often needed to overcome the work these proteins do to eliminate drugs and toxins alike from the body. Cytochrome P450 protein levels are elevated when a drug binds to and activates their respective regulators, such as nuclear receptors, which in turn activates cytochrome P450 genes’ expression. In particular, PXR regulates the expression of a central player in drug metabolism, CYP3A4.
PXR activates drug-removing cytochrome P450 hitmen
“PXR is a transcription factor that regulates the gene expression of CYP3A4, and when a drug binds to and activates PXR, it upregulates CYP3A4,” said corresponding author Taosheng Chen, Ph.D., St. Jude Department of Chemical Biology & Therapeutics. “CYP3A4 metabolizes more than half of drugs on the market, so it’s clear how important it is.”
CYP3A4 inhibitors, such as ritonavir, have shown benefit when used in combination with the anti-SARS-CoV-2 drug Paxlovid by stopping its active ingredient, nirmatrelvir, from being metabolized by CYP3A4 too quickly. Directly inhibiting PXR activity represents an alternative solution to control drug metabolism by CYP3A4. If drug-metabolizing proteins like CYP3A4 are the hired goons, then PXR represents the mob boss.
Corresponding author Taosheng Chen, Ph.D. (left), co-first author Sergio Chai, Ph.D. (center) and co-author Shyaron Poudel, St. Jude Department of Chemical Biology & Therapeutics investigated the inhibitor/activator binding mechanisms of pregnane X receptor (PXR), a protein implicated in drug metabolism. Credit: St. Jude Children’s Research Hospital
The researchers’ challenge was overcoming generations of PXR evolution, which has turned the protein into a juggernaut of ligand promiscuity. “Lots of compounds can bind to PXR,” explained Chen.
“There are even very small compounds that by themselves, are inactive. But if you combine a few of them, they can bind to different areas of PXR and together activate it.” The flexibility that allows it to bind thousands of different compounds also means inhibiting its function requires a deft touch.
Previous work from the Chen lab on PXR inhibitor discovery identified the inhibitor SPA70 as a potent candidate. But as a testament to PXR’s unique capabilities, very minor changes to SPA70 flipped it into an activator rather than an inhibitor. In this study, Chen and his team leveraged chemical and structural studies to understand the molecular basis behind the subtle differences between activator and inhibitor binding.
Structures pinpoint the activator/inhibitor gatekeeper
To address these differences, the researchers used X-ray crystallography to obtain the first-ever atomic structures of PXR bound to an inhibitor, presenting four new PXR structures with different inhibitors bound. These could be used to compare old and new structures of PXR bound to activators with almost identical chemical structures to the inhibitors to pinpoint the exact protein regions that govern PXR activity.
“The activator and inhibitor structures are very similar, except that the activators interact with a region of PXR we call activation function-2, AF2,” said Chen. “The inhibitor failed to interact effectively.”
The AF2 region appeared to be crucial in determining whether a drug would function as an activator or inhibitor. “When you have an activator, the conformation of the AF2 is different from that induced by an inhibitor. And it would favor either co-activator or co-repressor recruitment, respectively,” explained Chen. “So, it’s almost like a gatekeeper.”
Building on the information gained from these structures, the researchers found they could flip the drugs between activator and inhibitor by rationally adding or taking away pieces of the molecules based on the identified “hot spots” within the protein.
Chen hopes these findings will spark new research into more effective PXR inhibitors, which could potentially be used to prevent PXR-mediated drug metabolism.
More information:
Efren Garcia-Maldonado et al, Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR, Nature Communications (2024). DOI: 10.1038/s41467-024-48472-1
Citation:
Novel inhibitor insights offer pathway to preventing PXR-associated drug resistance (2024, May 15)
retrieved 22 May 2024
from https://medicalxpress.com/news/2024-05-inhibitor-insights-pathway-pxr-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @americanfork.business
